Company

They hold keys to unanswered questions.
They open up new ones.
They drive science forward.

Samples can be revolutionary.


This humbles us and motivates us in everything that we do.



About Purigen Biosystems

Purigen Biosystems' transformative platform provides a hands-free solution for extracting, enriching and quantifying DNA and RNA from biological samples. Our proprietary approach uses isotachophoresis (ITP), an electric-field driven technique for purifying, focusing, and/or separating species. The application of ITP to purify and quantify nucleic acids from complex biological samples was pioneered by Purigen co-founder, Stanford Professor Juan G. Santiago. Purigen's system is compatible with a range of samples including: mammalian cells, FFPE and FNA tissue biopsies, plasma, blood, and buccal swabs.

Purigen is proudly affliated with StartX Med, a Stanford-University-affliated nonprofit technology accelerator, and the California Life Sciences Institute’s (CLSI) FAST Advisory Program.


Careers

The right team of professionals have come together to make Purigen Biosystems into a dynamic scientific company.

Executive Management

Joseph J. Victor

Executive Chairman and Interim CEO

Joe Victor joined the Purigen Biosystems board at the time of the Series A funding in March of 2016. Mr. Victor is also a Venture Partner at 5AM Ventures, a leading venture capital firm with offices in San Francisco and Boston focused on building next-generation life science companies. Prior to joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify and develop innovative technologies in the Life Sciences research tools markets. Prior to Startide, Mr. Victor served as CEO of DVS Sciences (acquired by Fluidigm), and Applied Precision (acquired by GE Healthcare). He currently serves as Executive Chairman on the boards of 5AM portfolio companies Biodesy and Precision Nanosystems and on the boards of Glencoe Software and RareCyte. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Prior to his eighteen years in Life Sciences, Mr. Victor held various executive management and technical positions in the high technology, aviation, and energy markets. Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Klint Rose, Ph.D.

CSO and Co-founder

Dr. Klint Rose co-founded Purigen Biosystems in 2012. Dr. Rose was previously an R&D Manager at QuantaLife, Inc. (acquired by Bio-Rad), where he played a key leadership role in the development, launch, and support of their droplet digital PCRTM product. He previously directed a portfolio of several successful projects at Lawrence Livermore National Laboratory (LLNL) with applications in sample preparation, desalination, and nanomanufacturing. Dr. Rose is an expert in microfluidics and electrokinetics, with over 15 years of experience in the space. Klint received his B.S. and M.S. in mechanical engineering from the Massachusetts Institute of Technology (MIT) and his Ph.D. from Stanford University.

Amy Hiddessen, Ph.D.

CTO and Co-founder

Dr. Amy Hiddessen has served as CTO for Purigen since its founding in 2012. Dr. Hiddessen was previously Director of Product Development at QuantaLife, Inc. (acquired by Bio-Rad), where she led the ddPCRTM emulsion chemistry and instrumentation from the early stages of R&D through successful product commercialization. Prior to QuantaLife, Dr. Hiddessen directed multiple cell biology and biomolecular detection projects as Principal Investigator of her own lab at Lawrence Livermore National Laboratory. She has over 15 years of experience developing innovative chemistries and tools for life and materials sciences applications, resulting in numerous patents and publications. Amy received her B.S. in chemical engineering from Stanford University, and M.S. and Ph.D. degrees in chemical engineering at the University of Pennsylvania.

Steve Reichenbach

CFO

Steve Reichenbach brings over 30 years of financial and operational experience to his role at Purigen. Mr. Reichenbach was the CFO at Flow International for 13 years before joining Applied Precision Inc., which was acquired by GE Healthcare. Mr. Reichenbach holds a BA in finance from the University of Washington.

Pam Delucchi

SVP of Operations

Pam Delucchi has over 25 years of experience in the life science industry in both startup and large company environments. Ms. Delucchi was previously the Vice President of the Global Reagents Business at Fluidigm. Prior to joining Fluidigm, she was Vice President of Operations at DVS Sciences (acquired by Fluidigm in 2014), Vice President Operations and Quality at Panomics (acquired bv Affymetrix in 2008), and Director of Manufacturing and Program Management at Clontech Laboratories, Inc. (acquired by BD Biosciences in 2000). Pam received her M.S. in Microbiology and Genetic Engineering from San Francisco State University.

Board of Directors

Joseph J. Victor

Executive Chairman of the Board of Directors

Joe Victor joined the Purigen Biosystems board at their Series A funding in March of 2016. Mr. Victor is also a Venture Partner at 5AM Ventures, a leading venture capital firm with offices in San Francisco and Boston focused on building next-generation life science companies. He is currently Executive Chairman on the boards of 5AM portfolio companies Biodesy and Precision Nanosystems, and is on the boards of Glencoe Software and RareCyte. Mr. Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation. Prior to joining 5AM Ventures, Mr. Victor served as CEO of Startide Sciences, a 5AM Ventures portfolio company. Mr. Victor also served as CEO of DVS Sciences (acquired by Fluidigm), and Applied Precision (acquired by GE Healthcare). Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington.

Andrew Schwab

Managing Partner – 5AM Ventures

Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital where he was involved with such companies as Cubist, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Bird Rock Bio, Cleave, DVS (acquired by Fluidigm), Flexion (NASDAQ: FLXN), GenePeeks, Ikaria (acquired by Mallinckrodt and spun-out Bellerophon (NASDAQ: BLPH)), Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), Pear Therapeutics, Precision NanoSystems, Purigen, Synosia (acquired by Biotie) and Viveve (NASDAQ: VIVE). Mr. Schwab serves on the Board of Trustees of the California Academy of Sciences and Davidson College and was recently appointed to the Board of Directors of the National Venture Capital Association (NVCA). Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team. Mr. Schwab is based in the San Francisco, CA office.

Mitchell Mutz, Ph.D.

Investment Director – Roche Venture Fund

Mitchell Mutz, Ph.D., is an investment director at Roche Venture Fund. Prior to this, he served as the President and Chief Scientific Officer with Amplyx Pharmaceuticals for nearly a decade. Mitchell co-founded Amplyx Pharmaceuticals with Professor Gerald Crabtree of Stanford University in 2007. Mitchell has a Ph.D. in chemistry and began his career in drug discovery in 1997 at the Palo Alto Institute for Molecular Medicine. He later worked at Scios, Inc. and while there worked on a project to discover small molecule therapeutics to treat Alzheimer’s disease. In 2000, he left Scios to start Labcyte, Inc. There he participated in raising the initial venture financing of the company, as well as working as the principal scientist. He has his MA from the University of London and his PhD from the University of Rochester. 

Bill W. Colston, Ph.D.

CEO of HealthTell, Inc.

Dr. Bill Colston was previously the CEO and scientific founder of QuantaLife Inc., a successful biotechnology startup company. QuantaLife developed the most accurate genetic analysis system in the world, now sold internationally (droplet digital PCR™). Dr. Colston raised multiple rounds of private funding, moving from concept to manufactured product in a fraction of the time of comparable companies in this space. QuantaLife grew exponentially during his tenure, from the four scientific founders during the inception in 2008 to over sixty employees by the time it was sold to BioRad in 2011. Prior to QuantaLife, Dr. Colston worked within the University of California (UC) National Labs for almost 20 years, ultimately serving in multiple different senior leadership roles. A prolific scientific writer and inventor, he has authored numerous publications and patents. Dr. Colston received his BS in biology from the University of Texas, Austin, in 1989 and his Ph.D. in biomedical engineering from the University of California, Davis, in 1997.

Amy Hiddessen, Ph.D.

Purigen CTO and Co-founder

Dr. Amy Hiddessen has served as CTO for Purigen since its founding in 2012. Dr. Hiddessen was previously Director of Product Development at QuantaLife, Inc. (acquired by Bio-Rad), where she led the ddPCRTM emulsion chemistry and instrumentation from the early stages of R&D through successful product commercialization. Prior to QuantaLife, Dr. Hiddessen directed multiple cell biology and biomolecular detection projects as Principal Investigator of her own lab at Lawrence Livermore National Laboratory. She has over 15 years of experience developing innovative chemistries and tools for life and materials sciences applications, resulting in numerous patents and publications. Amy received her B.S. in chemical engineering from Stanford University, and M.S. and Ph.D. degrees in chemical engineering at the University of Pennsylvania.

Klint Rose, Ph.D.

Purigen CSO and Co-founder

Dr. Klint Rose co-founded Purigen Biosystems in 2012. Dr. Rose was previously an R&D Manager at QuantaLife, Inc. (acquired by Bio-Rad), where he played a key leadership role in the development, launch, and support of their droplet digital PCRTM product. He previously directed a portfolio of several successful projects at Lawrence Livermore National Laboratory (LLNL) with applications in sample preparation, desalination, and nanomanufacturing. Dr. Rose is an expert in microfluidics and electrokinetics, with over 15 years of experience in the space. Klint received his B.S. and M.S. in mechanical engineering from the Massachusetts Institute of Technology (MIT) and his Ph.D. from Stanford University.

Advisory Board

Juan Santiago, Ph.D.

Scientific Advisor and Co-founder

Juan Santiago received his MS and PhD in Mechanical Engineering from the University of Illinois at Urbana-Champaign in 1995.  His research includes the development of microsystems for on-chip chemical and biochemical analysis, methods for sample preparation, and electric-field based deionization methods. Applications of this work include molecular diagnostics, drug discovery, and the production of drinking water.  He is a Fellow of the American Physical Society, a Fellow of the American Society of Mechanical Engineering, and a Fellow of the American Institute for Medical and Biological Engineering.  He is an Editorial Advisory Board of the journal Analytical Chemistry, and an Associate Editor of the journal Microfluidics and Nanofluidics.  He is co-founder of several companies in the microfluidics area, co-inventor of micron-resolution particle image velocimetry (Micro-PIV), and director of the Stanford Microfluidics Laboratory.  He has served as Associate Editor of the journal Lab on a Chip (’08-’13).  Santiago has given more than 30 keynote and named lectures and more than 150 additional invited lectures.  As one measure of impact, his work is cited about 1500 times per year (Google Scholar h index of 65).  He has graduated 27 PhD students and advised eight postdoctoral researchers. 19 of his former advisees are now professors at major universities.  He has authored and co-authored over 160 archival publications and 200 conference papers, and holds 47 patents (24 of which are currently licensed).